Loading…
Analysis of clinicopathological features and prognosis of double primary cervical cancer and ovarian cancer based on SEER database
Objective Double primary cervical cancer and ovarian cancer refer to the simultaneous or successive appearance of cervical cancer and ovarian cancer in the same patient. Due to the low incidence, there are few relevant reports. Therefore, this study is the first population-based analysis of the clin...
Saved in:
Published in: | Journal of cancer research and clinical oncology 2023-12, Vol.149 (18), p.16407-16415 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c303t-63e467c091596fb1e855f2334a6ca42267fc565183afa243050ead521365f9853 |
container_end_page | 16415 |
container_issue | 18 |
container_start_page | 16407 |
container_title | Journal of cancer research and clinical oncology |
container_volume | 149 |
creator | Han, Yue Wang, Xiaoying Li, Xinyue Chen, Jiahui Ouyang, Ling Li, Yan |
description | Objective
Double primary cervical cancer and ovarian cancer refer to the simultaneous or successive appearance of cervical cancer and ovarian cancer in the same patient. Due to the low incidence, there are few relevant reports. Therefore, this study is the first population-based analysis of the clinicopathological features as well as the prognostic status of double primary cervical cancer and ovarian cancer. We look forward to providing a reference for future clinical diagnosis and treatment.
Methods
In this study, 473 cases of double primary cervical cancer and ovarian cancer were collected from 1975 to 2019 through the SEER database. Double primary cancers were considered non-synchronous when they were diagnosed more than 6 months apart and were classified as Group A. Double primary cancers were considered synchronous when the interval between diagnosis of the two tumors was less than or equal to 6 months and was classified as group B.
Results
In this study, the incidence of double primary cervical cancer and ovarian cancer accounted for 0.39% of primary cervical cancer and 0.24% of primary ovarian cancer in the same period. 80% of patients developed second cancer within 107 months of their first cancer being diagnosed. Compared with non-synchronous cancer, synchronous cancer is mainly characterized by simultaneous bilateral ovarian involvement and early clinical stage, but highly malignant, high lymph node metastasis rate, and poor prognosis.
Conclusion
Most patients developed second cancer within 107 months of their first cancer being diagnosed. Age at diagnosis, bilateral ovarian invasion, the interval between diagnoses, pathological type and stage of ovarian cancer, and grade of cervical cancer are important factors affecting survival, which still needs to be confirmed by more extensive studies in future. |
doi_str_mv | 10.1007/s00432-023-05373-y |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2864896399</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2864896399</sourcerecordid><originalsourceid>FETCH-LOGICAL-c303t-63e467c091596fb1e855f2334a6ca42267fc565183afa243050ead521365f9853</originalsourceid><addsrcrecordid>eNp9kU1LAzEQhoMoWKt_wNOCFy-rSWaT3T2WUj-gIPhxDtM0qVu2SU12hV795aYfInjwNDMvzzsw8xJyyegNo7S8jZQWwHPKIacCSsg3R2TAthIDEMdkQFnJcsGZPCVnMS5pmkXJB-Rr5LDdxCZm3ma6bVyj_Rq7d9_6RaOxzazBrg8mZujm2Tr4hfMHeu77WWuS1qwwbDJtwufOodGlfsf7TwwNuh9phtEk0WUvk8lzNscOt8o5ObHYRnNxqEPydjd5HT_k06f7x_Fommug0OUSTCFLTWsmamlnzFRCWA5QoNRYcC5Lq4UUrAK0yAugghqcp5NBCltXAobker83XfHRm9ipVRO1aVt0xvdR8UoWVS2hrhN69Qdd-j6kT22pqi5rwQQkiu8pHXyMwVh1-IViVG1jUftYVIpF7WJRm2SCvSkm2C1M-F39j-sb0k6Q4w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2889795153</pqid></control><display><type>article</type><title>Analysis of clinicopathological features and prognosis of double primary cervical cancer and ovarian cancer based on SEER database</title><source>Springer Nature</source><creator>Han, Yue ; Wang, Xiaoying ; Li, Xinyue ; Chen, Jiahui ; Ouyang, Ling ; Li, Yan</creator><creatorcontrib>Han, Yue ; Wang, Xiaoying ; Li, Xinyue ; Chen, Jiahui ; Ouyang, Ling ; Li, Yan</creatorcontrib><description>Objective
Double primary cervical cancer and ovarian cancer refer to the simultaneous or successive appearance of cervical cancer and ovarian cancer in the same patient. Due to the low incidence, there are few relevant reports. Therefore, this study is the first population-based analysis of the clinicopathological features as well as the prognostic status of double primary cervical cancer and ovarian cancer. We look forward to providing a reference for future clinical diagnosis and treatment.
Methods
In this study, 473 cases of double primary cervical cancer and ovarian cancer were collected from 1975 to 2019 through the SEER database. Double primary cancers were considered non-synchronous when they were diagnosed more than 6 months apart and were classified as Group A. Double primary cancers were considered synchronous when the interval between diagnosis of the two tumors was less than or equal to 6 months and was classified as group B.
Results
In this study, the incidence of double primary cervical cancer and ovarian cancer accounted for 0.39% of primary cervical cancer and 0.24% of primary ovarian cancer in the same period. 80% of patients developed second cancer within 107 months of their first cancer being diagnosed. Compared with non-synchronous cancer, synchronous cancer is mainly characterized by simultaneous bilateral ovarian involvement and early clinical stage, but highly malignant, high lymph node metastasis rate, and poor prognosis.
Conclusion
Most patients developed second cancer within 107 months of their first cancer being diagnosed. Age at diagnosis, bilateral ovarian invasion, the interval between diagnoses, pathological type and stage of ovarian cancer, and grade of cervical cancer are important factors affecting survival, which still needs to be confirmed by more extensive studies in future.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-023-05373-y</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Cancer Research ; Cervical cancer ; Diagnosis ; Hematology ; Internal Medicine ; Lymph nodes ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastases ; Oncology ; Ovarian cancer ; Patients ; Population studies ; Prognosis</subject><ispartof>Journal of cancer research and clinical oncology, 2023-12, Vol.149 (18), p.16407-16415</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c303t-63e467c091596fb1e855f2334a6ca42267fc565183afa243050ead521365f9853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Han, Yue</creatorcontrib><creatorcontrib>Wang, Xiaoying</creatorcontrib><creatorcontrib>Li, Xinyue</creatorcontrib><creatorcontrib>Chen, Jiahui</creatorcontrib><creatorcontrib>Ouyang, Ling</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><title>Analysis of clinicopathological features and prognosis of double primary cervical cancer and ovarian cancer based on SEER database</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><description>Objective
Double primary cervical cancer and ovarian cancer refer to the simultaneous or successive appearance of cervical cancer and ovarian cancer in the same patient. Due to the low incidence, there are few relevant reports. Therefore, this study is the first population-based analysis of the clinicopathological features as well as the prognostic status of double primary cervical cancer and ovarian cancer. We look forward to providing a reference for future clinical diagnosis and treatment.
Methods
In this study, 473 cases of double primary cervical cancer and ovarian cancer were collected from 1975 to 2019 through the SEER database. Double primary cancers were considered non-synchronous when they were diagnosed more than 6 months apart and were classified as Group A. Double primary cancers were considered synchronous when the interval between diagnosis of the two tumors was less than or equal to 6 months and was classified as group B.
Results
In this study, the incidence of double primary cervical cancer and ovarian cancer accounted for 0.39% of primary cervical cancer and 0.24% of primary ovarian cancer in the same period. 80% of patients developed second cancer within 107 months of their first cancer being diagnosed. Compared with non-synchronous cancer, synchronous cancer is mainly characterized by simultaneous bilateral ovarian involvement and early clinical stage, but highly malignant, high lymph node metastasis rate, and poor prognosis.
Conclusion
Most patients developed second cancer within 107 months of their first cancer being diagnosed. Age at diagnosis, bilateral ovarian invasion, the interval between diagnoses, pathological type and stage of ovarian cancer, and grade of cervical cancer are important factors affecting survival, which still needs to be confirmed by more extensive studies in future.</description><subject>Cancer Research</subject><subject>Cervical cancer</subject><subject>Diagnosis</subject><subject>Hematology</subject><subject>Internal Medicine</subject><subject>Lymph nodes</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Patients</subject><subject>Population studies</subject><subject>Prognosis</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kU1LAzEQhoMoWKt_wNOCFy-rSWaT3T2WUj-gIPhxDtM0qVu2SU12hV795aYfInjwNDMvzzsw8xJyyegNo7S8jZQWwHPKIacCSsg3R2TAthIDEMdkQFnJcsGZPCVnMS5pmkXJB-Rr5LDdxCZm3ma6bVyj_Rq7d9_6RaOxzazBrg8mZujm2Tr4hfMHeu77WWuS1qwwbDJtwufOodGlfsf7TwwNuh9phtEk0WUvk8lzNscOt8o5ObHYRnNxqEPydjd5HT_k06f7x_Fommug0OUSTCFLTWsmamlnzFRCWA5QoNRYcC5Lq4UUrAK0yAugghqcp5NBCltXAobker83XfHRm9ipVRO1aVt0xvdR8UoWVS2hrhN69Qdd-j6kT22pqi5rwQQkiu8pHXyMwVh1-IViVG1jUftYVIpF7WJRm2SCvSkm2C1M-F39j-sb0k6Q4w</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Han, Yue</creator><creator>Wang, Xiaoying</creator><creator>Li, Xinyue</creator><creator>Chen, Jiahui</creator><creator>Ouyang, Ling</creator><creator>Li, Yan</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20231201</creationdate><title>Analysis of clinicopathological features and prognosis of double primary cervical cancer and ovarian cancer based on SEER database</title><author>Han, Yue ; Wang, Xiaoying ; Li, Xinyue ; Chen, Jiahui ; Ouyang, Ling ; Li, Yan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c303t-63e467c091596fb1e855f2334a6ca42267fc565183afa243050ead521365f9853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cancer Research</topic><topic>Cervical cancer</topic><topic>Diagnosis</topic><topic>Hematology</topic><topic>Internal Medicine</topic><topic>Lymph nodes</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Patients</topic><topic>Population studies</topic><topic>Prognosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Han, Yue</creatorcontrib><creatorcontrib>Wang, Xiaoying</creatorcontrib><creatorcontrib>Li, Xinyue</creatorcontrib><creatorcontrib>Chen, Jiahui</creatorcontrib><creatorcontrib>Ouyang, Ling</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep (ProQuest)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Han, Yue</au><au>Wang, Xiaoying</au><au>Li, Xinyue</au><au>Chen, Jiahui</au><au>Ouyang, Ling</au><au>Li, Yan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of clinicopathological features and prognosis of double primary cervical cancer and ovarian cancer based on SEER database</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><date>2023-12-01</date><risdate>2023</risdate><volume>149</volume><issue>18</issue><spage>16407</spage><epage>16415</epage><pages>16407-16415</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Objective
Double primary cervical cancer and ovarian cancer refer to the simultaneous or successive appearance of cervical cancer and ovarian cancer in the same patient. Due to the low incidence, there are few relevant reports. Therefore, this study is the first population-based analysis of the clinicopathological features as well as the prognostic status of double primary cervical cancer and ovarian cancer. We look forward to providing a reference for future clinical diagnosis and treatment.
Methods
In this study, 473 cases of double primary cervical cancer and ovarian cancer were collected from 1975 to 2019 through the SEER database. Double primary cancers were considered non-synchronous when they were diagnosed more than 6 months apart and were classified as Group A. Double primary cancers were considered synchronous when the interval between diagnosis of the two tumors was less than or equal to 6 months and was classified as group B.
Results
In this study, the incidence of double primary cervical cancer and ovarian cancer accounted for 0.39% of primary cervical cancer and 0.24% of primary ovarian cancer in the same period. 80% of patients developed second cancer within 107 months of their first cancer being diagnosed. Compared with non-synchronous cancer, synchronous cancer is mainly characterized by simultaneous bilateral ovarian involvement and early clinical stage, but highly malignant, high lymph node metastasis rate, and poor prognosis.
Conclusion
Most patients developed second cancer within 107 months of their first cancer being diagnosed. Age at diagnosis, bilateral ovarian invasion, the interval between diagnoses, pathological type and stage of ovarian cancer, and grade of cervical cancer are important factors affecting survival, which still needs to be confirmed by more extensive studies in future.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1007/s00432-023-05373-y</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0171-5216 |
ispartof | Journal of cancer research and clinical oncology, 2023-12, Vol.149 (18), p.16407-16415 |
issn | 0171-5216 1432-1335 |
language | eng |
recordid | cdi_proquest_miscellaneous_2864896399 |
source | Springer Nature |
subjects | Cancer Research Cervical cancer Diagnosis Hematology Internal Medicine Lymph nodes Medical prognosis Medicine Medicine & Public Health Metastases Oncology Ovarian cancer Patients Population studies Prognosis |
title | Analysis of clinicopathological features and prognosis of double primary cervical cancer and ovarian cancer based on SEER database |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T19%3A31%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20clinicopathological%20features%20and%20prognosis%20of%20double%20primary%20cervical%20cancer%20and%20ovarian%20cancer%20based%20on%20SEER%20database&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Han,%20Yue&rft.date=2023-12-01&rft.volume=149&rft.issue=18&rft.spage=16407&rft.epage=16415&rft.pages=16407-16415&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-023-05373-y&rft_dat=%3Cproquest_cross%3E2864896399%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c303t-63e467c091596fb1e855f2334a6ca42267fc565183afa243050ead521365f9853%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2889795153&rft_id=info:pmid/&rfr_iscdi=true |